Petros Pharmaceuticals Announces Closing of $5.7 Million Registered Direct Offering
Petros Pharmaceuticals (Nasdaq: PTPI) has closed a registered direct offering, raising approximately $5.7 million from its largest and other existing investors. The funds will support the expansion of its men's health platform and provide working capital. CEO Fady Boctor emphasized that this financing is vital for the continued development of its product STENDRA and other promising assets, particularly following STENDRA's strong market performance in recent quarters.
- Raised approximately $5.7 million for business expansion.
- Strong performance of STENDRA in recent quarters.
- Funding will enhance the men's health platform and support new asset development.
- Dependence on a single product (Stendra) and distributor.
- History of significant financial losses.
- Risks associated with regulatory approvals and market acceptance.
NEW YORK, Oct. 19, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced the closing of its previously announced registered direct offering with the company's largest and other existing investors for gross proceeds of approximately
Petros Pharmaceuticals intends to use the net proceeds from this offering for expansion of its men's health platform and for working capital and general corporate purposes.
"This additional raise, in which our largest stockholder provided half of the total proceeds, is instrumental in helping us to continue to develop our men's health platform, which includes enhancing the position of STENDRA, while also continuing to develop promising new assets that we believe will help usher in new ways of thinking about men's health. This financing comes on the heels of STENDRA's strong performance in the market over the last several quarters and helps us to maintain our trajectory toward becoming a leader in the category moving into 2022," commented Fady Boctor, Petros Pharmaceuticals' President and Chief Commercial Officer.
Katalyst Securities LLC acted as financial advisor to Petros Pharmaceuticals with respect to this transaction.
About Petros Pharmaceuticals
Petros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men's health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including, but not limited to erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie's disease, hormone health and substance use disorders.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as "plans", " expects" or "does not expect", "proposed", "is expected", "budgets", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, Petros Pharmaceuticals' ability to execute on its business strategy, including its plans to develop and commercialize its product candidates; Petros Pharmaceuticals' ability to comply with obligations as a public reporting company; the ability of Petros Pharmaceuticals to timely and effectively implement controls and procedures required by Section 404 of the Sarbanes-Oxley Act of 2002; the risk that the financial performance of Petros Pharmaceuticals may not be as anticipated by the merger transactions that resulted in Petros Pharmaceuticals' creation; risks resulting from Petros Pharmaceuticals' status as an emerging growth company, including that reduced disclosure requirements may make shares of Petros Pharmaceuticals common stock less attractive to investors; risks related to Petros Pharmaceuticals' history of incurring significant losses; risks related to Petros Pharmaceuticals' dependence on the commercialization of a single product, Stendra®, and on a single distributor thereof; risks related to Petros Pharmaceuticals' commercial supply agreement with Vivus, including the risk that Petros Pharmaceuticals may not be able to obtain sufficient quantities of Stendra® in a timely manner or on commercially viable terms; risks related to Petros Pharmaceuticals' ability to obtain regulatory approvals for, or market acceptance of, any of its products or product candidates; and the expected or potential impact of the novel coronavirus pandemic, including the emergence of new variants, such as the Delta variant, and the related responses of governments, consumers, customers, suppliers, employees and Petros Pharmaceuticals, on Petros Pharmaceuticals' business, operations, employees, financial condition and results of operations. A discussion of these and other factors, including risks and uncertainties with respect to Petros Pharmaceuticals, and other factors described in Petros Pharmaceuticals' most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K filed with the Securities and Exchange Commission, which can be reviewed at www.sec.gov. Petros Pharmaceuticals disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
View original content:https://www.prnewswire.com/news-releases/petros-pharmaceuticals-announces-closing-of-5-7-million-registered-direct-offering-301403411.html
SOURCE Petros Pharmaceuticals, Inc.
FAQ
What is the purpose of the $5.7 million offering by PTPI?
Who were the main investors in Petros Pharmaceuticals' recent offering?
What financial performance risks does PTPI face after the offering?
When did Petros Pharmaceuticals announce the closing of the offering?
What are the key products associated with Petros Pharmaceuticals?
